CALT
Calliditas Therapeutics AB
$23.2
Earnings Summary
Revenue | $198.17Mn |
Net Profits | $6.45Mn |
Net Profit Margins | 3.25% |
Highlights
Calliditas Therapeutics AB’s revenue jumped +Inf% since last year same period to $198.17Mn in the Q3 2021. On a quarterly growth basis, Calliditas Therapeutics AB has generated +Inf% jump in its revenue since last 3-months.
Calliditas Therapeutics AB’s net profit jumped 104.67% since last year same period to $6.45Mn in the Q3 2021. On a quarterly growth basis, Calliditas Therapeutics AB has generated 104.03% jump in its net profits since last 3-months.
Calliditas Therapeutics AB’s net profit margin jumped NaN% since last year same period to 3.25% in the Q3 2021. On a quarterly growth basis, Calliditas Therapeutics AB has generated NaN% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Calliditas Therapeutics AB post its latest quarter earnings
EPS Estimate Current Quarter | 0.27 |
EPS Estimate Current Year | 0.27 |
Highlights
Calliditas Therapeutics AB’s earning per share (EPS) estimates for the current quarter stand at 0.27 - a 178.77% jump from last quarter’s estimates.
Calliditas Therapeutics AB’s earning per share (EPS) estimates for the current year stand at 0.27.
Key Ratios
Key ratios of the Calliditas Therapeutics AB post its Q1 2023 earnings
Earning Per Share (EPS) | 0 |
Highlights
Calliditas Therapeutics AB’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2023. This indicates that the Calliditas Therapeutics AB has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2019-06-30 | 0 | 0.49 | +Inf% |
2019-03-31 | 0 | -0.25 | -Inf% |
2019-12-31 | 0 | -0.12 | -Inf% |
2019-09-30 | 0 | -0.27 | -Inf% |
Company Information
Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
Organisation | Calliditas Therapeutics AB |
Headquarters | Kungsbron 1, D5, Stockholm, Sweden, 111 22 |
Employees | 102 |
Industry | Health Technology |
CEO | Renee J. Aguiar-Lucander |
Discover More Earning Stocks in Health Technology Sector
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*